| Item Type: | Article |
|---|---|
| Title: | Weekly 24-Hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer |
| Creators Name: | Kretzschmar, A., Reichardt, P., Thuss-Patience, P.C., Hohenberger, P., Benter, T., Doerken, B. and Koehne, C.H. |
| Abstract: | Purpose: This study was performed to investigate the activity and safety of high dose 5-fluorouracil (5-FU) given as a weekly 24-hour infusion in combination with folinic acid plus mitomycin C in patients with advanced gastric cancer. Patients and Methods: Chemonaive patients with locally advanced inoperable, recurrent or metastatic gastric cancer were treated with 15 mg/m2 i.v. mitomycin C as bolus on day 1 of a 7-week cycle followed by a 2-hour infusion of folinic acid (500 mg/m2) and a 24-hour infusion of 5-FU (2,600 mg/m2) given on days 1, 8, 15, 22, 29, and 36 as outpatient treatment. Results: Thirty evaluable patients (median age 58 years and median ECOG performance status 1) received 1–4 cycles (median 3). 53% of the patients had liver metastases. Treatment-related toxicity was low with 10% of patients experiencing diarrhea ≥grade 3, 3% mucositis grade 3 and 3% nausea grade 3 (CTC). Hematological toxicity was mild with 13% thrombopenia grade 3 and no leukopenia grade 4. Eleven patients achieved a partial remission (major response rate 37%; 95% confidence interval 22–53%). Median time to progression was 5 months and median overall survival time was 7 months. Conclusion: This regimen is a well-tolerated outpatient treatment for patients with advanced gastric cancer with efficacy being comparable to other chemotherapy protocols. |
| Keywords: | Folinic Acid, Gastric Cancer, 5-Fluorouracil, Mitomycin C |
| Source: | Oncology |
| ISSN: | 0890-9091 |
| Volume: | 59 |
| Number: | 1 |
| Page Range: | 14-17 |
| Date: | June 2000 |
| Official Publication: | https://doi.org/10.1159/000012130 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page


Tools
Tools

